BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35787940)

  • 1. Immune checkpoint molecules in neuroblastoma: A clinical perspective.
    Pathania AS; Prathipati P; Murakonda SP; Murakonda AB; Srivastava A; Avadhesh ; Byrareddy SN; Coulter DW; Gupta SC; Challagundla KB
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):247-258. PubMed ID: 35787940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
    Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
    Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
    Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
    Front Immunol; 2019; 10():2816. PubMed ID: 31849984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of neuroblastoma cell lines with uncommon TAZ
    Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells.
    McNerney KO; Karageorgos SA; Hogarty MD; Bassiri H
    Front Immunol; 2020; 11():873. PubMed ID: 32457760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
    Lucarini V; Melaiu O; D'Amico S; Pastorino F; Tempora P; Scarsella M; Pezzullo M; De Ninno A; D'Oria V; Cilli M; Emionite L; Infante P; Di Marcotullio L; De Ioris MA; Barillari G; Alaggio R; Businaro L; Ponzoni M; Locatelli F; Fruci D
    J Exp Clin Cancer Res; 2022 Nov; 41(1):326. PubMed ID: 36397148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
    Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
    Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells.
    Vitale C; Bottino C; Castriconi R
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of immune evasion of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Morandi F; Bocca P; Gambini C; Ferrone S; Pistoia V
    Cancer Lett; 2005 Oct; 228(1-2):155-61. PubMed ID: 15923080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies.
    Marrella A; Dondero A; Aiello M; Casu B; Olive D; Regis S; Bottino C; Pende D; Meazza R; Caluori G; Castriconi R; Scaglione S
    Front Immunol; 2019; 10():1876. PubMed ID: 31447858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
    Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.
    Bottino C; Dondero A; Bellora F; Moretta L; Locatelli F; Pistoia V; Moretta A; Castriconi R
    Front Immunol; 2014; 5():56. PubMed ID: 24575100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.